Julie Rubinstein, President and COO of Adaptive Biotechnologies Corporation, has reported multiple transactions involving the company's common stock. The transactions, filed on October 16, 2026, highlight a series of acquisitions and disposals of shares, reflecting her active management of her ownership stake in the company.
Adaptive Biotechnologies Corporation, based in Seattle, Washington, specializes in the development of biological products, particularly in the life sciences sector. The company is classified under the SIC code 2836, which pertains to biological products (no diagnostic substances). Recent filings indicate that the company is navigating a competitive landscape, likely influenced by other firms in the biotechnology space.
The filing details several transactions that took place on October 14, 15, and 16, 2026. Rubinstein acquired 11,881 shares at a price of $12.14 per share and disposed of shares at various prices, including $25.57 and $25.82. Notably, she sold 11,581 shares at a price of $24.21 on October 16, 2026. Following these transactions, Rubinstein's total ownership stands at 377,802 shares.
This update may impact various stakeholders, including investors and employees, as it reflects Rubinstein's ongoing commitment to managing her investment in the company. The transactions were executed under a Rule 10b5-1 trading plan, which allows for pre-scheduled trading to mitigate concerns over insider trading.
Looking ahead, it remains to be seen whether further filings will provide additional insights into Rubinstein's strategic decisions or the company's future direction. The filing does not specify any upcoming actions or events.